Fracture risk assessment (FRAX) without BMD and risk of major osteoporotic fractures in adults with type 1 diabetes

Champakanath, Anagha; Keshawarz, Amena; Pyle, Laura; Snell-Bergeon, Janet K.; Shah, Viral N.

Affiliations

¹Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States of America

Abstract and keywords

Objective: To evaluate the association between Fracture Risk Assessment Tool (FRAX) without bone mineral density (BMD) and risk for major osteoporotic fractures (MOF) in type 1 diabetes.

Methods: Subjects with type 1 diabetes and without diabetes from the ‘Coronary Artery Calcification in Type 1 Diabetes’ study were included. Risk for MOF was calculated using FRAX-based clinical risk factors and without BMD at visit 3 (2006–2008). Incident fractures were defined as fractures that occurred between visit 3 and visit 4 (2013–2017). Survival models were used to study the predictability of new MOF by diabetes status.

Results: 346 type 1 diabetes (mean age 43.3 ± 9, BMI 26.4 ± 5, diabetes duration 29.4 ± 8.6 years, A1c 7.8 ± 1.1) and 411 controls (mean age 46.9 ± 9 years, BMI 26.3 ± 5 kg/m2, A1c 5.5 ± 0.4) were analyzed in this study. In unadjusted survival analysis, the FRAX score without BMD was significantly associated with MOF (HR 1.08, 95% CI: 1.04–1.13, p < 0.0001), and remained significantly associated after adjustment for age and sex (HR 1.09, 95% CI: 1.04–1.15, p = 0.0007) and type 1 diabetes (HR 1.08, 95% CI: 1.04–1.12, p = 0.0002). In the fully adjusted model (adjusted for age, sex and type 1 diabetes), the FRAX score without BMD was the only variable significantly associated with risk of MOF (HR 1.08, 95% CI: 1.02–1.14, p = 0.006).

Conclusion: Clinical use of FRAX without BMD is useful tool in identifying adults with type 1 diabetes at higher risk for MOF risk and may help clinicians to guide therapeutic decision-making in this high fracture risk population.

Keywords: Type 1 diabetes; Fracture risk; FRAX; Fracture risk assessment tool; Bone mineral density; Major osteoporotic fracture

Links

DOI: 10.1016/j.bone.2020.115614

PubMed: 32853853

WoS: 000604733200015

History

Received: 2019-12-18

Revised: 2020-08-21

Accepted: 2020-08-21

Online: 2020-08-24

Cited Works (5)

Year	Entry
2011	Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV. Interpretation and use of FRAX in clinical practice. Osteoporos Int. September 2011;22(9):2395-2411.
2007	Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos Int. April 2007;18(4):427-444.
2011	Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer ES, Ensrud KE, Donaldson MG, Cauley JA, Harris TB, Koster A, Womack CR, Palermo L, Black DM; Study of Osteoporotic Fractures (SOF); Osteoporotic Fractures in Men (MrOS); Health, Aging, and Body Composition (Health ABC) Research Groups. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. June 1, 2011;305(21):2184-2192.
2012	Giangregorio LM, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res. February 2012;27(2):301-308.
2010	Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD; Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Can Med Assoc J. November 23, 2010;182(17):1864-1873.